Abstract
100% of primary human hepatocytes infected with an adenoviral vector carrying β-galactosidase expressed the exogenous gene. Expression was also achieved in > 40% of adult mouse hepatocytes in vivo. Normal levels of activity were achieved in mouse ornithine transcarbamylase (OTC)-deficient primary hepatocytes using another adenoviral vector carrying human OTC cDNA. Study of OTC-deficient primary human hepatocytes from a single patient confirmed the utility of adenoviral delivery of OTC. We describe adenoviral-mediated exogenous gene expression in human and mouse hepatocytes in vitro and in mouse liver in vivo. Data suggest that adenoviral vectors may be useful for correcting OTC deficiency.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1580-1586 |
| Number of pages | 7 |
| Journal | Journal of Clinical Investigation |
| Volume | 92 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1993 |
Keywords
- β-galactosidase
- Gene therapy
- Human
- Liver
- Ornithine transcarbamylase
ASJC Scopus subject areas
- General Medicine